From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target α5β1 integrin
Clinical data
558480-40-3 N
UNII 496K5Z02NW YesY
KEGG D06319 YesY
Chemical data
Formula C6434H9942N1706O2040S52
145.5 kDa
 N (what is this?)  (verify)

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]

It is thought to reduce metastases. Early results show potential in renal cell cancers. [ref needed]


  1. ^ Ng, CM; Bai, S; Takimoto, CH; Tang, MT; Tolcher, AW (2009). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients". Cancer chemotherapy and pharmacology 65 (2): 207–17. doi:10.1007/s00280-009-1023-8. PMID 19468731. 

External links[edit]